Merck KGaA (ETR:MRK)

Market Cap	58.46B +22.8%
Revenue (ttm)	21.14B -0.4%
Net Income	2.37B -17.2%
EPS	5.45 -17.3%
Shares Out	434.78M
PE Ratio	24.67
Forward PE	15.51
Dividend	2.20 (1.61%)
Ex-Dividend Date	Apr 27, 2026

Volume	260,313
Open	133.95
Previous Close	134.45
Day's Range	132.95 - 136.90
52-Week Range	100.70 - 148.80
Beta	0.81
Analysts	Buy
Price Target	154.21 (+12.64%)
Earnings Date	Nov 12, 2026

About Merck KGaA

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1668
• Employees: 62,136
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: MRK

Financial Performance

In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.

Analyst Summary

According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is €154.21, which is an increase of 12.64% from the latest price.

Price Target

€154.21

(12.64% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error